Personalized Cancer Vaccine Market - By Vaccine Type, By Technology, By Indication, By End Use - Global Forecast, 2025-2034

Personalized Cancer Vaccine Market Size

The global personalized cancer vaccine market size was valued at USD 216.9 million in 2024. The market is expected to grow from USD 272.1 million in 2025 to USD 2.2 billion in 2034, at a CAGR of 26.4% during the forecast period, according to the latest report published by Global Market Insights Inc.

This growth is attributed to the increasing incidence of cancer along with advancements in genomics and precision medicine. Breakthroughs in genomics and next-generation sequencing (NGS) have revolutionized cancer treatment. These technologies enable the identification of tumor-specific neoantigens, which are critical for designing personalized vaccines. The cost of sequencing has dropped significantly, making it more accessible for clinical use.
 

Additionally, the integration of artificial intelligence and bioinformatics is streamlining the development of personalized cancer vaccines by predicting immunogenic neoantigens and optimizing mRNA constructs, that further contributes to market growth. The personalized cancer vaccine pipeline is rapidly expanding, with over 78 clinical trials currently underway globally. Most trials are in Phase 1, targeting cancers like melanoma, glioblastoma, and pancreatic cancer. Companies such as BioNTech and Moderna are leading efforts with platforms like iNeST and mRNA Design Studio. These trials demonstrate strong immune responses and promising clinical outcomes, including tumor shrinkage and prolonged progression-free survival.
 

A personalized cancer vaccine is a custom-made treatment that trains the patient's own immune system to identify and destroy their specific cancer cells. It works by analyzing a patient's tumor to identify unique mutations, or neoantigens, and then creating a vaccine to stimulate a targeted immune response against them. This differs from traditional vaccines, which are not tailored to individual genetic differences, and can help establish long-term immunity against the cancer. Major players in the industry are Dendreon Pharmaceuticals, BioNTech, Immatics, Elicio Therapeutics and Evaxion Biotech. These players dominated the market by adopting various strategies such as product expansion and establishing global distribution networks.
 

Personalized cancer vaccine market has witnessed steady growth, growing from USD 91 million in 2021 to USD 162.1 million in 2023. Robust funding from both public and private sectors is fueling research and development in personalized cancer vaccines. The U.S. National Cancer Institute (NCI) allocated USD 7.2 billion in 2024, with USD 3.1 billion directed toward research project grants. Private foundations and biotech firms are also investing heavily, with companies such as Moderna and BioNTech securing partnerships and grants for vaccine development. Despite recent political shifts affecting mRNA funding, global interest remains strong. Public-private collaborations and initiatives like the Cancer Moonshot are vital in sustaining innovation and accelerating clinical translation, making funding a critical growth enabler, fueling the growth of the market.
 

Personalized Cancer Vaccine Market Trends

• The global rise in cancer incidence is fueling demand for targeted therapies. Personalized cancer vaccines align with the broader shift toward precision medicine and immunotherapy. Additionally, aging populations and increasing healthcare expenditure globally are creating a favorable environment for personalized treatments, especially in North America and Asia-Pacific, where infrastructure and diagnostics are rapidly advancing.
   
• Moreover, there’s a surge in neoantigen-based vaccine development, especially for melanoma, NSCLC, and glioblastoma. In addition, clinical trials are increasingly integrating personalized vaccines with checkpoint inhibitors, enhancing efficacy. Patient-specific therapies are gaining traction due to reduced side effects and better outcomes.
   
• Moreover, AI-driven antigen prediction and mRNA platforms are being adopted by startups and academic institutions, indicating a shift toward more agile, tech-enabled research and development ecosystems.
   
• The surge in technological advancement such as the integration of AI and machine learning are revolutionizing vaccine design by predicting immunogenic neoantigens, optimizing mRNA sequences, and enhancing delivery systems.
   
• For instance, platforms such as BioNTech’s iNeST and Regeneron’s VelociVax enable rapid customization and scalability. Synthetic biology and cell-free DNA synthesis are streamlining production, while nanoparticle delivery systems improve targeting. These technologies reduce development time from months to weeks, making personalized vaccines more accessible and cost-effective. The convergence of genomics, bioinformatics, and AI is central to next-gen cancer immunotherapy.
   
• Regulatory bodies are adapting to the unique nature of personalized cancer vaccines. The U.S. FDA and Health Canada classify mRNA-based vaccines as biologics, requiring Biologics License Applications. The UK’s MHRA has issued draft guidelines for AI-designed mRNA therapies, marking a regulatory milestone. However, ambiguity remains around classification especially in the EU, where synthetic nucleic acid products may soon fall under ATMP regulations. Harmonizing global standards is crucial to accelerate approvals and ensure safety in this fast-evolving field.
   
• Further, personalized cancer vaccines are evolving from peptide-based to mRNA and dendritic cell platforms. Integration with checkpoint inhibitors and other therapies is becoming standard, enhancing immune response. Products such as autogene cevumeran by BioNTech show promise in pancreatic cancer. Vaccine design is increasingly patient-specific, leveraging tumor sequencing and AI to tailor treatment. This evolution reflects a shift from broad-spectrum to precision-targeted immunotherapies.
   
• Lastly, manufacturers are transitioning toward scalable, automated platforms using synthetic biology and AI. Companies are adopting GMP-compliant equipment and liquid handling systems to meet fast turnaround demands, often within 2-3 months from biopsy to administration.
   
• However, challenges remain in cost, quality control, and logistics. Collaborative models between biotech firms, hospitals, and research institutes are emerging to streamline manufacturing and expand access to personalized therapies, thereby driving the growth of the market.
   

Personalized Cancer Vaccine Market Analysis

Learn more about the key segments shaping this market

Download Free PDF

In 2021, the global market was valued at USD 91 million. The following year, it saw an increase to USD 121.3 million, and by 2023, the market further climbed to USD 162.1 million.
 

Based on vaccine type, the global market is divided into dendritic cell vaccines, mRNA-based vaccines, peptide-based vaccines, neoantigen-based vaccines and other vaccine types. The dendritic cell vaccines segment accounted for 85.5% of the market in 2024. The segment is expected to exceed USD 1.9 billion by 2034, growing at a CAGR of 26.3% during the forecast period.
 

• Dendritic cells (DCs) are the most potent antigen-presenting cells, capable of initiating robust T-cell responses. Their ability to process and present tumor-specific antigens makes them ideal for personalized cancer vaccines.
   
• DC vaccines have shown superior specificity, reduced off-target effects and improved patient outcomes. For instance, sipuleucel-T, the first FDA-approved DC vaccine, extended survival in prostate cancer patients. In 2024, over 60% of hospitals offering personalized therapies included DC-based treatments. This immunological precision is a major driver of market growth, especially as demand for safer, targeted therapies increases.
   
• Over 50 new clinical trials have been launched in the past 18 months targeting solid tumors with DC vaccines. These trials are exploring combinations with checkpoint inhibitors, chemotherapy, and radiotherapy. Promising results in glioblastoma, melanoma, and pancreatic cancer are encouraging further investment.
   
• For instance, the DCP-001 vaccine for acute myeloid leukemia showed efficacy in eradicating minimal residual disease. The growing pipeline and positive trial outcomes are accelerating regulatory approvals and market expansion.
   
• The mRNA-based vaccine segment of the market is projected to grow significantly with a CAGR of 27.5%. Recent studies show that mRNA vaccines significantly enhance survival when combined with immunotherapy.
   
• This synergy is attributed to mRNA’s ability to prime the immune system, making tumors more responsive to checkpoint inhibitors. Such outcomes are driving clinical interest and investment in mRNA-based cancer vaccines.
   

Based on the technology, the personalized cancer vaccine market is segmented into cell-based, mRNA PCV and other technologies. The cell-based segment dominated the market in 2024 with a revenue of USD 194.8 million.
 

• The personalized cancer vaccine uses patient-derived or engineered cells to present tumor-specific antigens, triggering robust immune responses. Sipuleucel-T, the first FDA-approved cell-based cancer vaccine, demonstrated extended survival in prostate cancer patients. Their dominance in clinical trials and hospital-based immunotherapy programs reflects strong clinical confidence and commercial viability, that further contributes to the growth of the market.
   
• Cell-based vaccines, especially those using dendritic cells, offer superior antigen presentation and T-cell activation. They can induce broad and durable immune responses, even in patients resistant to other therapies.
   
• Unlike peptide or recombinant vaccines, cell-based platforms mimic natural immune processes, enhancing specificity and reducing off-target effects. This targeted approach is crucial for treating heterogeneous tumors and minimizing toxicity, thereby driving the growth of the market.
   
• The mRNA PCV segment of the market is projected to grow significantly during the analysis period owing to technological advancements in mRNA platforms, Next-gen mRNA technologies such as self-amplifying RNA (saRNA) and circular RNA (circRNA) are improving vaccine stability, potency, and delivery. Lipid nanoparticle (LNP) systems enhance cellular uptake and reduce degradation, while AI-driven codon optimization boosts protein expression.
   

Based on indication, the personalized cancer vaccine market is classified into solid tumors and hematological malignancies. The solid tumors segment dominated the market in 2024 with USD 180.9 million.
 

• Personalized cancer vaccines (PCVs) offer targeted immunotherapy by leveraging tumor-specific neoantigens, making them particularly suitable for solid tumors. As cancer rates continue to rise, projected to reach 29.9 million cases by 2040, the demand for PCVs tailored to solid tumor indications is expected to surge.
   
• Solid tumors are the focus of over 50% of ongoing PCV clinical trials, including melanoma, NSCLC, glioblastoma, and pancreatic cancer. Trials such as Moderna’s mRNA-4157 and BioNTech’s autogene cevumeran have shown promising results, including 44% reduction in recurrence risk when combined with checkpoint inhibitors. These outcomes validate the efficacy of PCVs in solid tumors and accelerate regulatory approvals and clinical adoption. The growing trial pipeline reflects strong industry confidence and patient demand.  
   
• The hematological malignancies segment grew with a CAGR of 25.7% during the analysis period. PCVs are increasingly combined with CAR-T cell therapy and immune checkpoint inhibitors, enhancing immune responses in blood cancers. This synergy helps overcome tumor resistance and improves remission rates.
   
• For example, combining PCVs with PD-1 blockade in FL patients showed enhanced T-cell persistence and tumor regression. Such integrative approaches are redefining treatment paradigms and expanding the therapeutic potential of PCVs in hematologic oncology.

Learn more about the key segments shaping this market

Download Free PDF

Based on end use, personalized cancer vaccine market is classified into hospitals, cancer research centers, biotechnology and pharmaceutical companies and other end users. The hospitals segment dominated the market in 2024 and is expected to reach USD 1.3 billion by 2034.   
 

• Hospitals are the primary sites for vaccine administration, clinical trials, and patient monitoring, making them central to the delivery of personalized therapies. Their role in diagnostics and treatment coordination positions them as the most trusted and capable end-use channel for PCVs.
   
• Hospitals possess the necessary clinical infrastructure biopsy labs, sequencing facilities, and immunotherapy units to support personalized cancer vaccine workflows. Institutions like Mount Sinai and Dana-Farber have demonstrated successful Phase 1 trials of neoantigen vaccines within hospital settings. This capability allows for seamless integration of vaccine development, administration, and follow-up care, ensuring high-quality outcomes and patient safety, boosting market share for this segment.
   
• Hospitals are increasingly embedding personalized cancer vaccines into their oncology programs. Leading centers such as Mayo Clinic and Dana-Farber are developing patient-specific vaccines for lung, melanoma, and pancreatic cancers. These programs combine PCVs with standard treatments like chemotherapy and checkpoint inhibitors, enhancing efficacy and reducing recurrence. The institutional support for precision oncology is accelerating PCV adoption in hospital settings, that drives the growth of the market.

Looking for region specific data?

Download Free PDF

North America Personalized Cancer Vaccine Market

The North America market dominated the global personalized cancer vaccine industry with a market share of 46.2% in 2024.
 

• North America hosts 44% of global clinical trials for personalized cancer vaccines, with major activity in melanoma, NSCLC, and glioblastoma. Major biotech firms like Moderna, BioNTech, and Genentech are investing heavily in personalized cancer vaccine research and development in North America. The region benefits from public-private partnerships, NIH grants, and venture capital backing. For example, Merck’s USD 250 million investment in Moderna’s mRNA-4157 program highlights the financial momentum. This funding accelerates clinical development and commercialization.
   
• The FDA’s Office of Tissues and Advanced Therapies (OTAT) provide clear pathways for personalized cancer vaccine approval, including Breakthrough Therapy and Fast Track designations. Regulatory frameworks support cell-based, mRNA, and peptide vaccines, encouraging innovation and reducing time to market. This regulatory agility is a key driver of growth in North America.
   

The U.S. personalized cancer vaccine market was valued at USD 38 million and USD 50.6 million in 2021 and 2022, respectively. The market size reached USD 90.4 million in 2024, growing from USD 67.6 million in 2023.
 

• In 2024, the U.S. reported over 2 million new cancer cases, with solid tumors and hematologic malignancies dominating. Conventional therapies often fall short in advanced or refractory cases. Personalized cancer vaccines offer targeted, low-toxicity alternatives tailored to individual tumor profiles. This unmet need is fuelling demand for precision immunotherapies, especially in melanoma, NSCLC, and glioblastoma.
   
• The U.S. leads in next-generation sequencing (NGS) and AI-driven neoantigen prediction, enabling rapid and accurate vaccine design. Platforms like BioNTech’s iNeST and Moderna’s mRNA-4157 use machine learning to optimize antigen selection. These technologies reduce development time and improve efficacy, making personalized vaccines more scalable and accessible.
   

Europe Personalized Cancer Vaccine Market

Europe market accounted for USD 61.4 million in 2024 and is anticipated to show lucrative growth over the forecast period.
 

• Europe is a hub for personalized cancer vaccine trials, with major activity in Germany, the UK, and France. BioNTech’s autogene cevumeran and CureVac’s RNA-based vaccines are undergoing trials for pancreatic and colorectal cancers. The NHS Cancer Vaccine Launch Pad in the UK aims to enroll 10,000 patients by 2030, accelerating access to mRNA-based PCVs.
   
• Europe’s healthcare systems support precision oncology through integrated diagnostics, sequencing, and immunotherapy delivery. Hospitals and cancer centers in Germany, France, and the UK are equipped to handle personalized vaccine workflows.
   

Germany dominates the European personalized cancer vaccine market, showcasing strong growth potential.
 

• Germany hosts numerous clinical trials for personalized cancer vaccines, especially in breast, pancreatic, and glioblastoma cancers. Institutions such as University Hospital Tübingen and DKFZ are pioneering peptide-based and mRNA vaccine trials. BioNTech’s autogene cevumeran is undergoing Phase 2 trials for pancreatic cancer, showcasing Germany’s role in advancing individualized immunotherapies, driving market growth.
   
• Germany benefits from evolving EU and national regulatory frameworks that support personalized cancer vaccine development. The EMA’s PRIME designation and Germany’s flexible clinical trial regulations enable faster approvals for mRNA and dendritic cell vaccines. Regulatory clarity around neo-antigen targeting and cell-based therapies are encouraging innovation and market entry.
   

Asia Pacific Personalized Cancer Vaccine Market

The Asia Pacific market is anticipated to grow at the highest CAGR of 26.8% during the analysis timeframe.
 

• Asia Pacific accounts for 60% of global cancer cases, with countries like China reporting 4.57 million new diagnoses annually. The region faces high rates of solid tumors and hematologic malignancies, creating a pressing need for targeted therapies. Personalized cancer vaccines offer individualized treatment with fewer side effects, making them ideal for addressing the region’s diverse cancer landscape.
   
• Governments and private investors are pouring capital into biotech clusters across China, India, and South Korea. Contract development and manufacturing organizations (CDMOs) are expanding mRNA and viral-vector production capacity, reducing supply-chain risks and costs. Strategic partnerships, such as GSK’s collaboration with CureVac, are accelerating innovation and commercialization, contributing to market growth.
   

China personalized cancer vaccine market is estimated to grow with a significant CAGR, in the Asia Pacific market.
 

• The National Medical Products Administration (NMPA) has streamlined approval pathways for personalized cancer vaccines. China approved its first mRNA-DC personalized vaccine (LK101) for clinical trials in 2023. Regulatory reforms and fast-track designations are encouraging innovation and reducing time to market, making China a favorable environment for vaccine development.
   
• China’s leading hospitals such as Peking University Cancer Hospital and Fudan University Cancer Center are equipped with genomic labs, immunotherapy units, and clinical trial capabilities. These institutions support vaccine development, administration, and monitoring, making them central to the personalized cancer vaccine ecosystem.
   

Latin American Personalized Cancer Vaccine Market

Brazil leads the Latin American market, exhibiting remarkable growth during the analysis period.
 

• Brazil faces a significant cancer burden, with over 600,000 new cases annually, particularly in lung, breast, and colorectal cancers. Personalized cancer vaccines offer targeted, low-toxicity alternatives to conventional therapies, making them ideal for addressing Brazil’s diverse cancer landscape. The growing need for effective and individualized treatments is fueling market demand.
   
• Brazil’s regulatory agency ANVISA is increasingly supportive of personalized medicine. While definitions and frameworks are evolving, initiatives like the Brazilian Genomes Program and precision medicine policies are laying the groundwork for streamlined approvals. Regulatory clarity and alignment with global standards are encouraging innovation and market entry.
   

Middle East and Africa Personalized Cancer Vaccine Market

Saudi Arabia market to experience substantial growth in the Middle East and Africa market in 2024.
 

• Saudi Arabia faces a growing cancer burden, with solid tumors like breast, lung, and colorectal cancers among the most prevalent. The GCC region is expected to see a 140% increase in cancer cases by 2040. Personalized cancer vaccines offer targeted, low-toxicity alternatives to conventional therapies, making them ideal for addressing the country’s diverse cancer landscape and improving long-term outcomes.
   
• Saudi Arabia’s Vision 2030 prioritizes healthcare innovation and pharmaceutical self-sufficiency. Strategic investments in biomanufacturing, genomics, and vaccine development are transforming the country into a regional biotech hub.
   
• Saudi Arabia is investing in clinical trial capacity through partnerships with institutions such as KAIMRC and KFSHRC. Recent MoUs with biotech firms aim to host trials for cancer vaccines and immunotherapies. The Saudi Food and Drug Authority (SFDA) has also launched a national clinical trials registry to streamline oversight and compliance. These efforts are enhancing research capabilities and accelerating vaccine validation.
   

Personalized Cancer Vaccine Market Share

The global market is evolving rapidly, characterized by a dynamic yet moderately fragmented competitive landscape. Leading innovators such as BioNTech SE, Immatics, Elicio Therapeutics, Evaxion Biotech, and Dendreon Pharmaceuticals collectively hold approximately 70% of the global market share, driving growth through cutting-edge research, clinical advancements, and expansion into high-potential regions.
 

These companies are leveraging multi-pronged strategies including mergers and acquisitions, strategic collaborations, and innovative pricing models to strengthen their leadership positions. Their focus is on improving patient access to advanced immunotherapies, enhancing affordability, and addressing unmet needs in oncology.
 

Emerging biotech firms and AI-driven startups are complementing this growth by introducing next-generation vaccine platforms, such as mRNA-based and dendritic cell technologies, and novel delivery systems. Their impact is particularly strong in Asia-Pacific, Latin America, and the Middle East, where rising cancer prevalence and improving healthcare infrastructure are accelerating adoption.
 

As competition intensifies, market leaders are expanding their portfolios to deliver scalable, personalized solutions for solid tumors and hematologic malignancies. This innovation-driven approach is fueling sustained growth and transforming the global landscape of cancer immunotherapy.
 

Personalized Cancer Vaccine Market Companies

The company profile section includes both companies that have commercial drug available in the market as well as those that are onto clinical phase development. Prominent players operating in the personalized cancer vaccine industry are as mentioned below:

• BioNTech
• Moderna
• Immatics
• Candel Therapeutics
• Elicio Therapeutics
• Evaxion Biotech
• Immunomic Therapeutics
• Imugene
• Infinitopes
• OSE Immunotherapeutics
• Takis Biotech
• VacV Biotherapeutics
• ImmunityBio
• Agenus
• Dendreon Pharmaceuticals
   
• Dendreon Pharmaceuticals

Dendreon Pharmaceuticals leads the market with a share of ~30% in 2024. Dendreon pioneered cell-based cancer vaccines with Provenge, the first FDA-approved therapeutic vaccine for prostate cancer. Its expertise in autologous dendritic cell technology provides a strong foundation for personalized immunotherapy solutions.
 

• Immatics

Immatics specializes in T-cell receptor and neo-antigen discovery, offering highly targeted immunotherapies for solid tumors. Its proprietary XPRESIDENT platform ensures precision in antigen selection, positioning it as a frontrunner in personalized cancer vaccine innovation.
 

• Elicio  

Elicio stands out with its Amphiphile technology, which enhances lymph node targeting for robust immune activation. This unique delivery approach improves vaccine efficacy and durability, creating a competitive edge in immunotherapy.
 

Personalized Cancer Vaccine Industry News

• In March 2025, Everest Medicines a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, announced that the first patient has been dosed with the Company's internally developed personalized mRNA cancer vaccine EVM16 at Peking University Cancer Hospital in the investigator-initiated clinical trial (IIT) EVM16CX01. EVM16CX01 is the first-in-human (FIH) trial for EVM16, conducted jointly at Peking University Cancer Hospital and Fudan University Shanghai Cancer center, to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EVM16 as a monotherapy and in combination with a PD-1 antibody in patients with advanced or recurrent solid tumors.
   
• In March 2024, BioNTech presented clinical trial data for selected candidates from its oncology pipeline at the American Association for Cancer Research (“AACR”) Annual Meeting 2024 in San Diego, California. The oral and poster presentations will feature BioNTech’s investigational mRNA-based cancer vaccine and novel investigational antibody-drug conjugate (“ADC”) approaches.
   
• In December 2022, Moderna, Inc. a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck, known as MSD outside of the U.S. and Canada, announced that the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial of mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA, Merck’s anti-PD-1 therapy, demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of recurrence-free survival (RFS) versus KEYTRUDA alone for the adjuvant treatment of patients with stage III/IV melanoma following complete resection.
   

The personalized cancer vaccine market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 - 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Vaccine Type

• Dendritic cell vaccines
• mRNA-based vaccines
• Peptide-based vaccines
• Neoantigen-based vaccines
• Other vaccine types   

Market, By Technology

• Cell-based
• mRNA PCV
• Other technologies

Market, By Indication

• Solid tumors
• Hematological malignancies

Market, By End Use

• Hospitals
• Cancer research centers
• Biotechnology and pharmaceutical companies
• Other end use

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina 
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE